Investigation of the expression level of methylated septin 9 gene and serological carcinoembryonic antigen to diagnose colorectal cancer. A meta-analysis study Authors: Sharifeh Jorboniyan, Haniyeh Bashi Zadeh Fakhar, Mohammad-Esmaiel Akbari, Neda Izadi, Shaghayegh Rangraz Published: 2024 ABSTRACT IntroductionColorectal cancer (CRC) is a rising threat, necessitating accurate early diagnosis.AimThis meta-analysis scrutinised methylated septin 9 (SEPT9) and carcinoembryonic antigen (CEA) in CRC.MethodsFrom January 2012 to December 2022, databases including PubMed and Google Scholar were explored for English publications.ResultsThe meta-analysis revealed SEPT9’s superior diagnostic potential, boasting 71% sensitivity and 91% specificity, outshining CEA (49% and 53%). Notably, an 8-study analysis found a positive correlation between tumour grade and elevated CEA and SEPT9 levels, particularly in stages 3 and 4.ConclusionsThis meta-analysis supports SEPT9 as a potent CRC marker, urging its integration into diagnostic frameworks for enhanced precision and early intervention. The observed link between tumour grade and biomarker levels enhances clinical relevance. Implementing these findings promises improved CRC diagnosis precision, contributing to enhanced treatment outcomes and patient survival. Advocating for SEPT9’s inclusion alongside traditional markers like CEA, this study pioneers more effective colorectal cancer management strategies. Introduction Colorectal cancer (CRC) is the fourth leading cause of death due to cancer in the US [1]. Worldwide, there is an approximately 4.3% risk of CRC in men and women [2]. The death rate due to colon cancers has increased [3]. In the early 1990s, the death rate was 2.87 per 100,000, and it nearly doubled to 6.8 in 2017 [4]. The annual report of the National Cancer Registry of Iran (INCR: National cancer Registry in Iran) indicates CRC as the fourth most common cancer in males after stomach, bladder, and prostate [5]. The central, western and northern provinces of Iran have the highest incidence of CRC, while the southeastern provinces have the lowest incidence [6]. Several factors such as age, family history, and diet affect the occurrence of CRC [7]. According to studies, nearly 250 different mutations have been identified in patients with CRC, which is approximately equivalent to 55% of the known mutations related to mismatch repair (MMR) genes [8]. Abnormal methylation as a regulatory mechanism of gene expressions can be seen in tumour suppressor genes in various cancer types, including such as in [9]. Different epigenetic biomarkers are used for the diagnosis and prediction of prognosis of CRC [10]. Methylated septin 9 (mSEPT9) showed extremely high levels of methylation in CRC tissues, is used for CRC serological diagnosis, and has increased sensitivity [11]. CRC has rising incidence and mortality; thus, accurate and early diagnosis is important [12]. Colonoscopy is now the most direct technique to detect colorectal neoplasm [13]. Nonetheless, colonoscopy is not acceptable because of its possible risk and discomfort [14]. Non-invasive blood testing is easy to use with the possibility of frequent monitoring following diagnosis and treatment [15]. In a study in Germany, 63.4% (109/172) of cases did not accept screening colonoscopy, while 82.6% (90/109) selected blood testing [16]. The US Food and Drug Administration (FDA) recently approved detection of circulating mSEPT9 DNA in blood [17], which provided a commercially available alternative non-invasive test for the CRC screening [12]. Carcinoembryonic antigen (CEA), an oncofoetal antigen, is produced epithelial tumours of endodermal origin [18]. According to the American Society of Clinical Oncology, it should be assessed every 3 months for a minimum of 3 years in CRC patients in stages II and III after surgery [19]. Many studies have evaluated the diagnostic value of peripheral blood mSEPT9 to detect CRC; however, the diagnostic accuracy of CRC is highly varied [17, 20]. As a result, this study was conducted with the aim of investigating CEA and septin 9 in patients with CRC. Methods Aims We evaluated the specificity and sensitivity of septin 9 and carcinoembryonic antigen in patients with CRC. Design The Cochrane instructions [21], the PRISMA statement [22], and synthesis without meta-analysis (SWiM) guidelines were used for a systematic review of empirical quantitative studies [23]. Search methods Inclusion criteria The MEDLINE (PubMed interface), Psych-Info, Cochrane, and CINAHL (EBSCO interface) databases were searched between January 2012 and December 2022. MESH words were added to free text terms using a coherent search strategy: marker (CEA, septin 9, surgical, sensitivity, specificity) and cancer (CRC). We developed the search strategy for Medline followed by the other databases. More studies were found by searching the references of the selected studies, and it was the final stage to add the articles. Primary human studies in the period 2012-2022 that had CRC, studies that evaluated the sensitivity and specificity of CEA and septin 9 serum markers in CRC, published in English during 10 or feweer years ago, and assessing patients 18 years or older were considered. Exclusion criteria Studies with quantitative results.Studies considering familial or inherited CRC.In vitro or animal studies.Studies that did not indicate specificity or sensitivity of the markers. Studies with quantitative results. Studies with quantitative results. Studies considering familial or inherited CRC. Studies considering familial or inherited CRC. In vitro or animal studies. In vitro or animal studies. Studies that did not indicate specificity or sensitivity of the markers. Studies that did not indicate specificity or sensitivity of the markers. Study selection After choosing 2 researchers based on recent studies from databases from January 2012 to December 2022, the studies were chosen according to the first 100 abstracts obtained from the databases. Then, 2 different reviewers evaluated other abstracts, and in cases of uncertainty regarding including the abstracts, the full texts were read and relevant abstracts published from January 2012 were included considering the inclusion criteria. Some full-text articles not accepted by the first reviewer were reassessed by the second reviewer considering the exclusion criteria. Two independent reviewers assessed the eligibility. Also, case-control studies were not included. Search outcome A total of 12,288 records were detected. Duplicates (N = 9200) were not included. Based on the inclusion criteria, 3088 abstracts were reviewed, and extraction and review of 2988 abstracts were done. Also, 100 full-text articles were detected based on their abstract and title between January 2012 and December 2022. Also, 34 related published texts were found, but after reading the full texts, 21 articles were excluded because of reports excluded, inconsistency with the objectives of the study (n = 6), full text not available (n = 6), and being a review article (n = 1). Finally, 13 articles remained (Figure 1). Flow of information through the various phases of the systematic review Quality evaluation and data extraction The Quality Assessment Tool [24] assessed the quality of the quantitative articles. The quality of 34 articles was assessed using the STROBE list (Table I), and 13 appropriate articles were included. The full-text studies were evaluated prior to data extraction. This tool is adjusted based on a tool designed by the Effective Public Health Practice Project [25] applied in many systematic reviews [26, 27]. Table ISTROBE Statement – checklist of items that should be included in reports of observational studies Title and abstract 1(a) Indicate the study’s design with a commonly used term in the title or the abstract(b) Provide in the abstract an informative and balanced summary of what was done and what was found Introduction Background/rationale2Explain the scientific background and rationale for the investigation being reportedObjectives3State specific objectives, including any prespecified hypotheses Methods Study design4Present key elements of study design early in the paperSetting5Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collectionParticipants6(a) Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controlsCross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants(b) Cohort study – For matched studies, give matching criteria and number of exposed and unexposedCase-control study – For matched studies, give matching criteria and the number of controls per case Variables 7Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria if applicable Data sources/measurement 8*For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Bias 9Describe any efforts to address potential sources of bias Study size 10Explain how the study size was arrived at Quantitative variables 11Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 12(a) Describe all statistical methods, including those used to control for confounding(b) Describe any methods used to examine subgroups and interactions(c) Explain how missing data were addressed(d) Cohort study – If applicable, explain how loss to follow-up was addressed(c) Explain how missing data were addressed(d) Cohort study – If applicable, explain how loss to follow-up was addressedCase-control study – If applicable, explain how matching of cases and controls was addressedCross-sectional study – If applicable, describe analytical methods taking account of sampling strategy(e) Describe any sensitivity analyses Results Participants13*(a) Report numbers of individuals at each stage of study – e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed(b) Give reasons for non-participation at each stage(c) Consider use of a flow diagramDescriptive data14*(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders(b) Indicate number of participants with missing data for each variable of interest(c) Cohort study – Summaries follow-up time (e.g. average and total amount)Outcome data15*Cohort study – Report numbers of outcome events or summary measures over timeCase-control study – Report numbers in each exposure category, or summary measures of exposureCross-sectional study – Report numbers of outcome events or summary measuresMain results16(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included(b) Report category boundaries when continuous variables were categorised(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful periodOther analyses17Report other analyses done – e.g. analyses of subgroups and interactions, and sensitivity analyses Discussion Key results18Summaries key results with reference to study objectivesLimitations19Discuss limitations of the study, taking into account sources of potential bias or imprecision.Discuss both direction and magnitude of any potential biasInterpretation20Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidenceGeneralizability21Discuss the generalisability (external validity) of the study results Other information Funding22Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based*Give separate information for controls and cases in case-control articles and, if possible, for unexposed and exposed groups in cross-sectional and cohort studies. STROBE Statement – checklist of items that should be included in reports of observational studies Give separate information for controls and cases in case-control articles and, if possible, for unexposed and exposed groups in cross-sectional and cohort studies. The information were extracted as follows: author; country; year; age; number of patients; sex; cancer type; study type; sensitivity and specificity of septin 9; sensitivity and specificity of C; CEA measurement method; septin 9 (Table II) [28–39]. Two authors extracted data from each article, and in the case of disagreement a third opinion was used. Table IICharacteristics of the studiesNo.AuthorYearCountryPatients with CRCSexAgeaverageCut off Of CEACEA (positive) %Septin 9 (positive) %Type of manuscriptCorrelation between tumour grade and CEA.Septin9 levelsTimeSampleMeasurement of Septin9Measurement of CEASeptin9CEAAfter surgeryBefore surgerySen %Spe %% AddNPV %AUC %Accuracy %Sen %Spe %% AddNPV %AUC %Accuracy %MaleFemale1Ma [47]2019China117684967.3> 348.273.2Prospective studyIncreases * PlasmaPCREnzyme-linked ionosphere71.866.77150.578.960.52Toth [29]2012Germany187--67.8> 4.314.288.9Prospective studyIn stage 3 is 35.35 * PlasmaPCRCobas, Roche Diagnostics95.684.886.395.190.251.885.277.863.968.53Lu [39]2022China32621111558.6> 366.773Case control studyIn stage 4 is 81.8 * BloodPCR,Epi proColonCobas, Roche Diagnostics778888758282734Leung [40]2019Hung Kong187--66.1> 348.273.9Prospective studyStage 4 is 100% * PlasmaPCR,Epi proColonEnzyme-linked ionosphere73.572.581.962.273.347.979.38047.9605Lee [41]2013South Korea197--65.3> 344.764.7Case control studyStage 4 is 64.7% - * PlasmaRealtime, PCRRoche Diagnostic Corp36.690.680.457.662.920.86Eldeeb [42]2020China90553553.6> 2.915.838.4Prospective study- * BloodSunred ELISAElectrochemiluminescence immunoassay84.978.9758791.1817876767780.8777Sun [43]2019China557--65.2> 3.261.971.4Comparative study- * PlasmaEpi proColon, PCRElectrochemiluminescence7394.56396.583.552.491.865.48Song [44]2019China120724861.4> 344.286.7Comparative study- * PlasmaEpi proColon, PCRElectrochemiluminescence86.7-44.2-9Arellano [12]2022Spain32161250.75--53.5Prospective studyIncreases * PlasmaEpi proCo-Enzyme-linked Ion, PCR ionosphere55.610010023.559.310FU [33]2018China35120015160> 35061.2Prospective studyStage 4 is 87.5 % * PlasmaEpi proColon, PCRElectrochemiluminescence immunoassay61.298.493.786.880.28811Wu [45]2016China291183108-> 341.377Prospective study- * PlasmaEpi proColon, PCRElectrochemiluminescence76.695.994.980.688.286.341.312Yuan [46]2016China1871008763.8> 0.732.974.9Prospective study- * Plasma, tissuePCRElectrochemiluminescence62.691.792.858.877.773.332.913Ma [37]2021China103--67.3> 369.467.9Prospective studystage 3 is 76.7 % * Plasma, tissuePCREnzyme-linked ionosphere73.75081.838.17167.781.2 Characteristics of the studies Statistical analysis Homogeneity of findings was assessed through the results of inconsistency index (I2) value and Cochran’s Q test. For each study, false positive (FP), true positive (TP), false negative (FN), and true negative (TN) values were calculated according to the study data. A random-effects model calculated the overall effect. Forest plots containing descriptions of the results were applied to explain the estimates of the accuracy measures (specificities, sensitivities, negative and positive likelihood ratios (LRs), and diagnostic odds ratios (dOR), receiver operating characteristics curve (ROC) to describe the relationship between sensitivity and specificity of the test) with 95% confidence intervals (CIs). An area under the curve (AUC) close to one indicates good diagnostic performance of the test. Meta-Disc 1.4 was employed for all statistical analyses. Results Overall, 13 quantitative studies were analysed. Table II indicates the studies’ characteristics, which were all cross-sectional, conducted in China (N = 9), Spain (N = 1), Germany (N = 1), Hung Kong (N = 1), and South Korea (N = 1). Nine of these studies were prospective study studies, 2 were case-control studies, and 2 were comparative studies. The tested sample was reported in 9 studies on plasma, 2 studies on whole blood, and 2 studies on plasma and tissue. The total number of participants with colon cancer was 2745, and the patients’ mean age was 62.26 years. The mean level of CEA positivity was 44.79% and septin 9 was positive in 69.59%. In 8 studies, there was an incremental relationship between tumour grade and CEA, and septin 9 level was observed in cancer level 3 and 4. In 6 studies, sampling was done before colectomy surgery, and in 7 studies after it. In most studies, the septin 9 measurement method was by Epi proColon. Overall accuracy measurements for septin 9 as a predictor for colorectal cancer detection Using the results of 10 articles for septin 9, the total specificity and sensitivity were, respectively, 91% (95% CI: 90–92) and 71% (95% CI: 68–73) (Figure 2). The pooled positive and negative likelihood ratios (LRs) were, respectively, 6.07 (95% CI: 3.29–11.19) and 0.34 (95% CI: 0.25–0.47) (Figure 3). The pooled diagnostic odds ratio (dOR) based on the studies was high, at 19.76 (95% CI: 19.14–42.74) (Figure 4). The summary receiver operating characteristic (sROC) for septin 9 was 0.84 (Figure 5). Forrest plot of sensitivity and specificity from accuracy studies of septin 9 for detection of colorectal cancer Forrest plot of likelihood ratios for positive and negative test results from studies of septin 9 for detection of colorectal cancer Forrest plot of diagnostic odds ratios (dOR) from accuracy studies of septin 9 for prediction of colorectal cancer Receiver operating characteristic curve for all studies of septin 9 for detection of colorectal cancer Overall accuracy measurements for carcinoembryonic antigen (CEA) as a predictor for colorectal cancer detection Using the results of 3 articles for CEA, the overall specificity and sensitivity were, respectively, 53% (95% CI: 45–61) and 49% (95% CI: 43–56) (Figure 6). The pooled positive and negative likelihood ratios (LRs) were also, respectively, 1.64 (95% CI: 0.44–6.12) and 0.96 (95% CI: 0.39–2.35) (Figure 7). The pooled diagnostic odds ratios (dOR) based on the studies were high, at 1.69 (95% CI: 0.20–14.60) (Figure 8). The summary ROC (sROC) for CEA was 0.49 (Figure 9). Forrest plot of sensitivity and specificity from accuracy studies of carcinoembryonic antigen (CEA) for detection of colorectal cancer Forrest plot of likelihood ratios for positive and negative test results from studies of carcinoembryonic antigen (CEA) for detection of colorectal cancer Forrest plot of diagnostic odds ratios (dOR) from accuracy studies of carcinoembryonic antigen (CEA) for detection of colorectal cancer Receiver operating characteristic curve for all studies of carcinoembryonic antigen (CEA) for detection of colorectal cancer Discussion CRC is the third most common cancer in women and men [40]. According to estimates, about 1.2 million new CRC patients are diagnosed, and nearly 608,000 deaths due to CRC are reported every year [41]. Despite advancements in CRC treatment, the CRC advanced stage at diagnosis can lead to a very undesirable prognosis [42, 43]. Patient prognosis is improved by using screening tests, and these tests predict long-term survival by detecting tumours at early stages, resulting in reduced mortalities related to CRC [44]. Assessment of tumour markers in serum, like CEA, has a limited specificity and sensitivity for CRC diagnosis [45]. The septin 9 test can assess the SEPT9 gene methylation status, which is hypermethylated in CRC patients [37]. Recently, the SEPT9 gene methylation assay, as a blood-based test, was used for detection and screening of CRC [46, 47]. The hypermethylated SEPT9 gene is a biomarker to diagnose CRC in tumoral tissue and peripheral blood [12]. This systematic review attempts to assess carcinoembryonic antigen and methylated septin 9 for serological diagnosis and monitoring of CRC patients. Among the various methylated genes, septin 9 is used for the serological diagnosis of CRC, characterised by high sensitivity, and CEA measurement has also been recommended in cancer patients after surgery [36, 48, 49]. We included 13 studies. We obtained more definite results by the descriptive combination of studies. Assessment of biomarkers for the CRC diagnosis has a significant effect on its prognosis [50]. In general, in the review of the articles used in the current research, in 10 articles, the specificity and sensitivity of septin 9 were reported as 71% and 91%, respectively, and using the findings of 3 articles, the sensitivity and specificity of CEA were reported as 49 and 53%, respectively. This seems to indicate the importance of septin 9 as a biomarker in the diagnosis of CRC. Ma et al.’s study, using mSEPT9 methylation status to diagnose CRC, showed a significantly higher sensitivity than using CEA levels (73.2 vs. 48.2), and in general, in this study, mSEPT 9 was more sensitive for CRC diagnosis than was CEA and the combination of CEA, and mSEPT9 was more accurate [39]. Toth et al. declared similar findings, with respective specificities of 84.8% and 85.2% and sensitivities of 95.6% (88/92) and 51.8% (14/27) for mSEPT9 and CEA [29]. Also, mSEPT9 showed higher diagnostic value compared to CEA for sensitivity (73% vs. 52.4%) and specificity (94.5% vs. 91.8%) [34]. In the review of studies, we concluded that the sensitivity of the 2 tests increases with higher tumour staging. In the study by Ma et al., sensitivity showed an increase with increasing tumour staging (p = 0.04 and 0.04, respectively) [28]. In the study of Fu et al., the highest sensitivity was reported in stage 4 (87.5) [36]. In Lu et al.’s study, the sensitivity and specificity of both CEA and mSEPT9 tests increased in stages 3 and 4 more than stages 1 and 2 [30]. An AUC of close to one indicates a good diagnostic performance of the test. In our review, the AUC was reported as 0.84 for septin 9 and 0.49 for CEA. In the study of Eldeeb et al., the area under the curve was reported as 0.911 for septin 9 and 0.808 for CEA [33]. In Ma’s study, The accuracy regarding AUC of the methylated ratio and abundance for diagnosing CRC was nearly 0.71, which was more important than the unfavourable single methylated concentration performance (AUC = 0.55). The most favourable sensitivity for the detection of CRC was nearly 74% with a specificity of 50% for methylated abundance. The combined CEA and SEPT9 methylated abundance improved the performance with AUC to 0.92 [39]. In our study forest plots could explain the estimates of the accuracy measures – sensitivities, specificities, negative and positive likelihood ratios (LRs), and diagnostic odds ratios (dOR). The index of pooled positive and negative likelihood (LRs) for septin 9 was 6.07 against 1.64 for CEA and 0.34 for septin 9 against 0.96 for CEA. The index of pooled diagnostic odds ratios (dOR) was 19.76 for septin 9 and 1.69 for CEA. All these results obtained from the indicators indicate that septin 9 has a better and stronger diagnostic performance in identifying CRC. In the study of Xie et al. from 2019, according to the sensitivity and specificity indices and AUC, septin 9 biomarker was introduced as the best and most sensitive in detecting CRC [51]. The same results were found in the studies of Lu [30] and Allerano [12]. In most of the conducted studies, septin 9 measurement method was Epi proColon. The initial versions of the Epi proColon test (Epi proColon 2.0) possibly increased the SEPT9 performance in the diagnosis of CRC. The Epi proColon test, as a novel CRC screening test based on blood, can recognise the mSEPT9 (septin 9) gene in cell-free DNA collected from plasma [52]. In the study of Fu and Arellano, the (Epi proColon 2.0) method was also used [12]. Conclusions In this review study, we investigated the expression level of septin 9 and carcinoembryonic antigen to identify CRC. We found that there is a direct relationship between the expression level of these genes and the grading of the cancer stage, so that in some studies, stages 3 and 4 showed the highest levels of gene expression. Strong evidence showed that septin 9 can be used as an effective marker for the detection and prognosis of CRC, and it also showed better differentiation than CEA.